Lastly, the combinatorial application of AG and the insulin-re-sensitizing drug liraglutide, a glucagon-like peptide-1 (GLP-1) analog, was tested in the R6/2 Mouse Model of Huntington's disease (HD), resulting in the normalization of the chronically raised blood glucose levels as well as improved peripheral insulin sensitivity (HOMA-IR) and pancreatic ß-cell function (HOMA-ß) (Duarte et al., 2018). Here, GCG is linked to juvenile Huntington disease.